Recent Updates
Recently added Catalysts

6MHP

Phase 1

Melanoma | Monoclonal antibody | Oncology |Celldex Therapeutics, Inc.|Last Updated: Jul 16, 2024

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLEDDMCBiomarker
Total Trials2
Total Enrollment55

FDA Designations

No designations recorded

Clinical trial landscape

6MHP · 2 trials · 3 indications

Phase 1 2
NCT04364230Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)Melanoma
COMPLETED22 Analytics
NCT03617328Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV MelanomaMelanoma
COMPLETED33 Analytics
PHASE1COMPLETED
Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)
MelanomaUnlock trial analytics
PHASE1COMPLETED
Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma
MelanomaUnlock trial analytics

Study Endpoints

Primary Endpoints

Safety of CDX-1140 + melanoma peptide vaccine (6MHP and NeoAg-mBRAF) + PolyICLC
30 days after receiving the last dose of study drug

Number of participants with dose-limiting toxicities based on CTCAE v5.0

Immunogenicity: Estimate immune response rate to a melanoma vaccine combined with CDX-1140
Day 85 and/or Day 176

Number of participants with durable or persistent CD4+ Th1 responses to the melanoma vaccine at either day 85 or day 176, or both

Safety of CDX-1127 administered with a melanoma vaccine
30 days after receiving the last dose of study drug

Number of participants with dose-limiting toxicities based on CTCAE v5.0

Immunogenicity-Percent of patients with persistent CD4+ T cell responses to the 6MHP vaccine
Day 127 or Day 176 or both

Number of participants with CD4+ T cell responses to 6 MHP persisting to day 127 or later.

Secondary Endpoints

Immunogenicity: Impact of vaccine containing peptides plus CDX-1140 and polyICLC on regulatory T cells
Day 50
Immunogenicity: Impact of addition of CDX-1140 to melanoma vaccine on circulating regulatory T cells
Through Day 85
Immunogenicity: Impact of addition of CDX-1140 to melanoma vaccine on induction of CD4+ Th1 responses to vaccine antigens
Through Day 176
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
All ParticipantsEXPERIMENTAL6MHP (200mcg of each peptide) and 300mcg of NeoAg-mBRAF will be co-administered locally with 0.9mg of polyICLC and CDX-1140. There will be a dose escalation of CDX-1140 (50mcg, 200mcg, 800mcg, 3.0mg). A vaccine containing all of these components will be given on days 1, 22, 43, and 64. The vaccine will be given subcutaneously/intradermally.
Arm A: 6MHP/Montanide ISA-51 + polyICLC + CDX-1127EXPERIMENTAL200 mcg of 6MHP plus 0.9 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered subcutaneously on days 1, 8, 15, and 36. 200 mcg of 6MHP in Montanide ISA-51 adjuvant (without polyICLC) will be administered subcutaneously/intradermally on day 176. CDX-1127 (3mg/kg) will be administered intravenously on days 1, 36, and 78.
Arm B: 6MHP/Montanide ISA-51 + polyICLCEXPERIMENTAL200 mcg of 6MHP plus 0.9 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered subcutaneously on days 1, 8, 15, and 36. 200 mcg of 6MHP in Montanide ISA-51 adjuvant (without polyICLC) will be administered subcutaneously/intradermally on day 176.

Interventions

NameTypeDescription
6MHPDRUG6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
NeoAg-mBRAFDRUGBRAF 586-614 (V600E) peptide to which a histidine has been added to the N-terminus, resulting in BRAF 585-614 (V600E).
PolyICLCDRUGpolyICLC, local adjuvant
CDX-1140DRUGCDX-1140, local adjuvant
Montanide ISA-51DRUGMontanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant
CDX-1127DRUGCDX-1127, anti-CD27 monoclonal antibody
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites2

Main Inclusion Criteria: 1. a. For individuals with primary cutaneous, mucosal, or unknown melanoma, an individual must have stage IB ulcerated, II, III, or IV melanoma at original diagnosis or at restaging after recurrence, and be rendered clinically free of disease by surgery, other therapy, or s...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about 6MHP

What is 6MHP used for in melanoma?

6MHP is an investigational monoclonal antibody being studied for the treatment of melanoma, including ocular and uveal melanoma. It is currently in Phase 1 clinical development and has not been approved by the FDA. Two Phase 1 trials have been completed, enrolling a total of 55 patients.

Who makes 6MHP?

6MHP is being developed by Celldex Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol CLDX. The company is conducting clinical trials to evaluate the safety and efficacy of 6MHP in patients with melanoma.

What phase is 6MHP in?

6MHP is in Phase 1 clinical development. Two Phase 1 trials have been completed, with a total enrollment of 55 patients. The drug is investigational and has not received FDA approval. It is being studied for the treatment of melanoma, including ocular and uveal melanoma.

What clinical trials is 6MHP in?

6MHP has been studied in two completed Phase 1 trials. The first, NCT03617328, enrolled 33 patients with stage II-IV melanoma and evaluated vaccination with 6MHP with or without systemic CDX-1127. The second, NCT04364230, enrolled 22 patients with melanoma, including ocular and uveal melanoma, and tested a vaccine against neoantigen and shared antigens.

Is 6MHP the same as CDX-1127?

6MHP is not the same as CDX-1127. In clinical trial NCT03617328, 6MHP was administered with or without systemic CDX-1127, indicating they are separate agents. CDX-1127 is a systemic treatment, while 6MHP is a monoclonal antibody vaccine being studied for melanoma.